KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Pacira BioSciences (PCRX) over the last 15 years, with Sep 2025 value amounting to $7.5 million.

  • Pacira BioSciences' Change in Accured Expenses fell 32.68% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 147.84%. This contributed to the annual value of $11.7 million for FY2024, which is 153.18% up from last year.
  • Per Pacira BioSciences' latest filing, its Change in Accured Expenses stood at $7.5 million for Q3 2025, which was up 138.86% from -$19.4 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Change in Accured Expenses high stood at $22.5 million for Q4 2021, and its period low was -$25.1 million during Q1 2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was $3.5 million (2024), whereas its average is -$1.6 million.
  • In the last 5 years, Pacira BioSciences' Change in Accured Expenses plummeted by 8,640.71% in 2022 and then surged by 202.06% in 2023.
  • Pacira BioSciences' Change in Accured Expenses (Quarterly) stood at $22.5 million in 2021, then slumped by 83.53% to $3.7 million in 2022, then climbed by 11.18% to $4.1 million in 2023, then crashed by 120.06% to -$826,000 in 2024, then tumbled by 32.68% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, -$19.4 million for Q2 2025, and $4.7 million during Q1 2025.